Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-14 12:24 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | CVI Investments Inc. | 167,258 9.900% | 167,258 (New Position) | View |
2024-09-20 2:18 pm Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | Otsuka Masaya | 0 0.000% | -63 (Position Closed) | View |
2024-09-20 2:17 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Otsuka Masaya | 63 9.900% | 63 (New Position) | View |
2024-02-14 2:14 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | CVI Investments Inc. | 414,827 9.900% | 207,254 (+99.85%) | View |
2024-02-14 09:52 am Unchanged | 13G | Galmed Pharmaceuticals Ltd. GLMD | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | 0 (Unchanged) | View |
2024-02-12 4:15 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Baharaff Allen | 317,504 6.200% | 317,504 (New Position) | View |
2023-07-21 10:12 am Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | CVI Investments Inc. | 207,573 9.900% | 207,573 (New Position) | View |
2023-02-14 12:03 pm Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | BIOTECHNOLOGY VALUE FUND L P | 1,739,670 6.900% | -60,024 (-3.34%) | View |
2023-02-07 4:15 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Baharaff Allen | 4,560,356 17.300% | 147,250 (+3.34%) | View |
2022-02-14 08:14 am Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | Nantahala Capital Management LLC | 297,947 1.200% | -1,628,952 (-84.54%) | View |
2022-02-11 4:30 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Baharaff Allen | 4,413,106 16.900% | 132,514 (+3.10%) | View |
2022-01-27 4:32 pm Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | Ibex Investors LLC | 355,560 1.400% | -1,169,440 (-76.68%) | View |
2021-02-16 06:23 am Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Nantahala Capital Management LLC | 1,926,899 9.000% | 1,926,899 (New Position) | View |
2021-02-12 4:30 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Baharaff Allen | 4,280,592 19.300% | 82,241 (+1.96%) | View |
2021-02-12 4:13 pm Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | BIOTECHNOLOGY VALUE FUND L P | 1,799,694 8.400% | -32,790 (-1.79%) | View |
2021-01-15 11:16 am Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Ibex Investors LLC | 1,525,000 7.200% | 468,152 (+44.30%) | View |
2020-07-28 3:22 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Ibex Investors LLC | 1,056,848 5.010% | 1,056,848 (New Position) | View |
2020-02-14 3:18 pm Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | BIOTECHNOLOGY VALUE FUND L P | 1,832,484 8.700% | -46,024 (-2.45%) | View |
2020-02-13 4:30 pm Purchase | 13G | Galmed Pharmaceuticals Ltd. GLMD | Baharaff Allen | 4,198,351 19.200% | 98,333 (+2.40%) | View |
2020-02-13 10:11 am Sale | 13G | Galmed Pharmaceuticals Ltd. GLMD | 683 Capital Management LLC | 800,000 3.800% | -550,000 (-40.74%) | View |